Quarterly Cell & Gene Therapy Briefing Q4 2025

Course Provider
Emerging Therapy Solutions
Certifications
Learning Objectives
Identify utilization forecast updates from ETS and why there are changes from previous quarter(s)
Review of Tabelecleucel (Tab-cel) for Epstein-Barr virus-associated post-transplant lymphoproliferative disease
Discuss Omidubicel for Severe Aplastic Anemia
Discuss Marnetegragene autotemcel (Kresladi) for Leukocyte Adhesion Deficiency type 1
Describe Label update on Elevidys for Duchenne muscular dystrophy (DMD)
Course Offering: Seminar, Workshop, or Webinar - On-Demand (previously recorded)
Domain Focus: Care Delivery and Reimbursement Methods
Start Date:
End Date:
CE Credits: 1.00
Fee: $0.00
Learn More